A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sara Federico, MD
St. Jude Children's Research Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco
San Francisco, California, United States
Kieuhoa Vo, MDNot, yet, recruiting - Children'S Hospital of Colorado
Colorado Springs, Colorado, United States
Not, yet, recruiting - Motts Childrens Hospital
Ann Arbor, Michigan, United States
Rajen MOdy, MBBSNot, yet, recruiting - St. Jude Children'S Research Hospital
Memphis, Tennessee, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 10 Nov 2025
- Primary completion
- 1 Feb 2028
- Completion
- 1 Feb 2029
- Last update posted
- 4 Jun 2026
- Registered enrollment
- 54
- Registry id
- NCT07085338
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.